These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
307 related articles for article (PubMed ID: 28536738)
1. Selective targeted delivery of doxorubicin via conjugating to anti-CD24 antibody results in enhanced antitumor potency for hepatocellular carcinoma both in vitro and in vivo. Ma Z; He H; Sun F; Xu Y; Huang X; Ma Y; Zhao H; Wang Y; Wang M; Zhang J J Cancer Res Clin Oncol; 2017 Oct; 143(10):1929-1940. PubMed ID: 28536738 [TBL] [Abstract][Full Text] [Related]
2. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes. Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824 [TBL] [Abstract][Full Text] [Related]
3. A novel antibody targeting CD24 and hepatocellular carcinoma in vivo by near-infrared fluorescence imaging. He H; Tu X; Zhang J; Acheampong DO; Ding L; Ma Z; Ren X; Luo C; Chen Z; Wang T; Xie W; Wang M Immunobiology; 2015 Dec; 220(12):1328-36. PubMed ID: 26255089 [TBL] [Abstract][Full Text] [Related]
4. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo. Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307 [TBL] [Abstract][Full Text] [Related]
5. Anti-CD24 Antibody-Nitric Oxide Conjugate Selectively and Potently Suppresses Hepatic Carcinoma. Sun F; Wang Y; Luo X; Ma Z; Xu Y; Zhang X; Lv T; Zhang Y; Wang M; Huang Z; Zhang J Cancer Res; 2019 Jul; 79(13):3395-3405. PubMed ID: 30918001 [TBL] [Abstract][Full Text] [Related]
6. Antibody-based targeting of CD24 enhances antitumor effect of cetuximab via attenuating phosphorylation of Src/STAT3. Chen Z; Wang T; Tu X; Xie W; He H; Wang M; Zhang J Biomed Pharmacother; 2017 Jun; 90():427-436. PubMed ID: 28391164 [TBL] [Abstract][Full Text] [Related]
7. The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models. Wang S; Zhou R; Sun F; Li R; Wang M; Wu M Cancer Lett; 2017 Nov; 409():125-136. PubMed ID: 28923397 [TBL] [Abstract][Full Text] [Related]
8. Low-toxicity transferrin-guided polymersomal doxorubicin for potent chemotherapy of orthotopic hepatocellular carcinoma in vivo. Wei Y; Gu X; Cheng L; Meng F; Storm G; Zhong Z Acta Biomater; 2019 Jul; 92():196-204. PubMed ID: 31102765 [TBL] [Abstract][Full Text] [Related]
9. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model. Zhu F; Jiang Y; Luo F; Li P J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362 [TBL] [Abstract][Full Text] [Related]
10. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma. Chen X; Ding G; Gao Q; Sun J; Zhang Q; Du L; Qiu Z; Wang C; Zheng F; Sun B; Ni J; Feng Z; Zhu J PLoS One; 2013; 8(5):e63093. PubMed ID: 23675455 [TBL] [Abstract][Full Text] [Related]
11. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin. Zhang X; Li J; Yan M Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448 [TBL] [Abstract][Full Text] [Related]
12. Hepatocellular carcinoma dually-targeted nanoparticles for reduction triggered intracellular delivery of doxorubicin. Mezghrani O; Tang Y; Ke X; Chen Y; Hu D; Tu J; Zhao L; Bourkaib N Int J Pharm; 2015 Jan; 478(2):553-68. PubMed ID: 25455765 [TBL] [Abstract][Full Text] [Related]
13. A bispecific protein rG7S-MICA recruits natural killer cells and enhances NKG2D-mediated immunosurveillance against hepatocellular carcinoma. Wang T; Sun F; Xie W; Tang M; He H; Jia X; Tian X; Wang M; Zhang J Cancer Lett; 2016 Mar; 372(2):166-78. PubMed ID: 26791237 [TBL] [Abstract][Full Text] [Related]
14. Lactoferrin-modified PEGylated liposomes loaded with doxorubicin for targeting delivery to hepatocellular carcinoma. Wei M; Guo X; Tu L; Zou Q; Li Q; Tang C; Chen B; Xu Y; Wu C Int J Nanomedicine; 2015; 10():5123-37. PubMed ID: 26316745 [TBL] [Abstract][Full Text] [Related]
15. Cluster of differentiation 24 monoclonal antibody induces apoptosis in the osteosarcoma cells. Zhang YH; Wang ZY; Hao FY; Zhang L Eur Rev Med Pharmacol Sci; 2014; 18(14):2038-41. PubMed ID: 25027344 [TBL] [Abstract][Full Text] [Related]
16. Targeted Delivery of Doxorubicin via CD147-Mediated ROS/pH Dual-Sensitive Nanomicelles for the Efficient Therapy of Hepatocellular Carcinoma. Qu C; Li J; Zhou Y; Yang S; Chen W; Li F; You B; Liu Y; Zhang X AAPS J; 2018 Feb; 20(2):34. PubMed ID: 29476273 [TBL] [Abstract][Full Text] [Related]
17. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake. Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117 [TBL] [Abstract][Full Text] [Related]
18. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Murali M; Kumar AR; Nair B; Pavithran K; Devan AR; Pradeep GK; Nath LR Clin Transl Oncol; 2022 Mar; 24(3):407-431. PubMed ID: 34595736 [TBL] [Abstract][Full Text] [Related]
19. Anti-Sp17 monoclonal antibody-doxorubicin conjugates as molecularly targeted chemotherapy for ovarian carcinoma. Song JX; Li FQ; Cao WL; Jia X; Shi LN; Lu JF; Ma CF; Kong QQ Target Oncol; 2014 Sep; 9(3):263-72. PubMed ID: 23943313 [TBL] [Abstract][Full Text] [Related]
20. Improved therapeutic effect of DOX-PLGA-PEG micelles decorated with bivalent fragment HAb18 F(ab')(2) for hepatocellular carcinoma. Jin C; Qian N; Zhao W; Yang W; Bai L; Wu H; Wang M; Song W; Dou K Biomacromolecules; 2010 Sep; 11(9):2422-31. PubMed ID: 20831277 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]